565 Eli Lilly and Company $LLY Shares Bought by Portland Global Advisors LLC

Portland Global Advisors LLC grew its holdings in Eli Lilly and Company (NYSE:LLY – Free Report) by 63.8% during the 3rd quarter, HoldingsChannel reports. The firm owned 1,451 shares of the company’s stock after acquiring an additional 565 shares during the quarter. Portland Global Advisors LLC’s holdings in Eli Lilly and Company were worth $1,679,000 as of its most recent filing with the SEC.

Other institutional investors have also made changes to their positions in the company. Coastal Bridge Advisors LLC bought a new position in Eli Lilly and Company during the second quarter worth $2,959,000. Birinyi Associates Inc. raised its stake in Eli Lilly and Company by 32.6% during the 3rd quarter. Birinyi Associates Inc. now owns 1,460 shares of the company’s stock valued at $1,689,000 after purchasing an additional 359 shares during the last quarter. Bridges Investment Management Inc. raised its stake in Eli Lilly and Company by 38.5% during the 3rd quarter. Bridges Investment Management Inc. now owns 35,294 shares of the company’s stock valued at $40,838,000 after purchasing an additional 9,815 shares during the last quarter. Bernicke Wealth Management Ltd. bought a new stake in Eli Lilly and Company in the 3rd quarter valued at $5,001,000. Finally, Mosaic Family Wealth Partners LLC boosted its holdings in Eli Lilly and Company by 70.6% in the 2nd quarter. Mosaic Family Wealth Partners LLC now owns 3,455 shares of the company’s stock valued at $4,144,000 after purchasing an additional 1,430 shares during the period. 82.53% of the stock is currently owned by institutional investors.

Eli Lilly and Company Stock Down 0.3%

LLY opened at $1,346.40 on Friday. Eli Lilly and Company has a fifty-two week low of $850.51 and a fifty-two week high of $1,475.25. The company has a debt-to-equity ratio of 1.17, a current ratio of 1.39 and a quick ratio of 1.00. The firm’s fifty day moving average price is $1,268.06 and its two-hundred day moving average price is $1,119.25. The company has a market capitalization of $1.27 trillion, a P/E ratio of 43.70, a P/E/G ratio of 1.61 and a beta of 0.40.

Eli Lilly and Company (NYSE:LLY – Get Free Report) last announced its quarterly earnings results on Thursday, October 29th. The company reported $7.48 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.71 by $1.77. Eli Lilly and Company had a net margin of 31.90% and a return on equity of 86.76%. The firm had revenue of $24.40 billion for the quarter, compared to analyst estimates of $22.58 billion. During the same quarter in the previous year, the firm posted $7.02 EPS. The business’s revenue for the quarter was up 38.6% on a year-over-year basis. On average, analysts anticipate that Eli Lilly and Company will post 35.73 EPS for the current year.

Eli Lilly and Company Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Thursday, December 10th. Stockholders of record on Friday, November 13th will be given a dividend of $1.73 per share. This represents a $6.92 annualized dividend and a dividend yield of 0.5%. The ex-dividend date is Friday, November 13th. Eli Lilly and Company’s payout ratio is 22.46%.

Eli Lilly and Company News Roundup

Investors following LLY have been watching these news items:

  • Positive Sentiment: Lilly is expanding its oncology research through the acquisition of Calytrix Bio and a multi-target collaboration with Stipple Bio. The deals add programs and research capabilities, though their financial impact will depend on development progress. Article: Eli Lilly expands its oncology research platform
  • Negative Sentiment: Some coverage warns that Lilly’s roughly $1.4 trillion valuation leaves substantial expectations embedded in the shares. That could make the stock more sensitive to any slowdown in growth or disappointing clinical results. Article: Eli Lilly’s valuation is heavy with hope
  • Negative Sentiment: Healthcare ETFs reportedly sold Lilly shares, including $17.4 million from IYH and $42.3 million from XLV. These sales may add some market pressure, though they appear to be fund-position changes rather than a company-specific development. Article: IYH sells Eli Lilly shares

Wall Street Analysts Forecast Growth

Several analysts have issued reports on the stock. China Merchants Securities lowered shares of Eli Lilly and Company from a “buy” rating to a “hold” rating in a research report on Thursday, November 12th. Weiss Ratings raised shares of Eli Lilly and Company from a “buy (b)” rating to a “buy (b+)” rating in a research report on Friday, November 13th. HSBC upped their price objective on shares of Eli Lilly and Company from $850.00 to $940.00 and gave the company a “reduce” rating in a research report on Thursday, September 10th. JPMorgan Chase & Co. increased their target price on shares of Eli Lilly and Company from $1,500.00 to $1,650.00 and gave the company an “overweight” rating in a research note on Friday, October 30th. Finally, Barclays lifted their target price on Eli Lilly and Company from $1,400.00 to $1,550.00 and gave the stock an “overweight” rating in a research report on Monday, November 16th. One analyst has rated the stock with a Strong Buy rating, twenty-four have issued a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $1,422.00.

View Our Latest Stock Report on Eli Lilly and Company

Insider Buying and Selling at Eli Lilly and Company

In related news, EVP Anat Hakim sold 5,000 shares of the company’s stock in a transaction dated Monday, November 2nd. The shares were sold at an average price of $1,402.52, for a total value of $7,012,600.00. Following the sale, the executive vice president owned 4,137 shares of the company’s stock, valued at $5,802,225.24. The trade was a 54.72% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 0.14% of the company’s stock.

Eli Lilly and Company Profile

(Free Report)

Eli Lilly and Company is a global pharmaceutical company that discovers, develops, manufactures and markets medicines for people and animals. Its work spans areas including diabetes and obesity, cancer, immunology, neuroscience and pain management. The company’s medicines include treatments for diabetes and obesity, such as Mounjaro and Zepbound, as well as products for cancer and other conditions. Lilly also conducts research into new medicines and invests in the development of treatments across its therapeutic areas.

Recommended Stories

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY – Free Report).

Institutional Ownership by Quarter for Eli Lilly and Company (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.